Stock Financial Ratios


SRNE / Sorrento Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.40
Volume901,900.00
Market Cap ($M)0.19
Enterprise Value ($M)0.01
Book Value ($M)80.04
Book Value / Share1.59
Price / Book0.00
NCAV ($M)325.50
NCAV / Share6.46
Price / NCAV0.00
Income Statement (mra) ($M)
Revenue8.15
EBITDA-96.78
Net Income-63.94
Balance Sheet (mrq) ($M)
Cash & Equivalents38.32
Cash / Share0.76
Assets484.78
Liabilities346.48
Quick Ratio1.18
Current Ratio1.18
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.50
Return on Assets (ROA)-0.16
Return on Equity (ROE)-0.80
Identifiers and Descriptors
CUSIP83587F202
Central Index Key (CIK)850261
Industry Groups
SIC 8731 - Commercial Physical and Biological Research
Other Related CUSIPS
83587F952
83587F103
83587F902
Share Statistics
Common Shares Outstanding (M)79.32
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Assets Per Share9.63
Goodwill Per Share0.76
Property Plant And Equipment Per Share0.38
Deferred Income Tax Liabilities Per Share2.10
Equity Per Share2.60
Assets Current Per Share0.89
Liabilities Other Non Current Per Share0.00
Debt Per Share0.54
Intangibles Per Share0.00
Long Term Debt Per Share0.49
Treasury Stock Per Share0.98
Liabilities Per Share6.88
Accumulated Depreciation And Depletion Per Share0.16
Liabilities Current Per Share1.66
Cash And Equivalents Per Share0.76
Accounts Receivable Per Share0.00
Property Plant And Equipment Net Per Share0.38
Retained Earnings Per Share-3.53
Inventory Raw Materials Per Share0.00
Additional Paid In Capital Per Share7.11
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Minority Interest Per Share0.14
Property Plant And Equipment Gross Per Share0.54
Current Portion Of Long Term Debt Per Share0.05
Inventory Per Share0.00
Cash Per Share0.76
Liabilities And Stock Equity Per Share9.63
Assets Other Non Current Per Share0.07

Stock Research Report

At its core, Sorrento Therapeutics is an antibody-centric company and leverage its proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. The company's validated fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others. The company's vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as TCR-like antibodies. With LA Cell, Inc. (“LA Cell”), its joint venture with City of Hope, its objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, Sorrento Therapeutics has acquired and are assessing the regulatory and strategic path forward for its portfolio of late ...

Click for full article

Related News Stories

A Repeat Of The 1970s Inflation Or Worse?

2017-11-02 seekingalpha
Price action in markets often seems counterintuitive. Alasdair explained why stocks often decline even as earnings begin to rise, because stock prices have much more to do with flows of money than with fundamentals. Last week, Richard Maybury opined that an increase in monetary velocity may be starting, which could trigger general price inflation not unlike the 1970s. Indeed, your host's Inflation-Deflation Watch now appears to be entering an inflationary breakout. (16-1)

Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?

2017-10-13 seekingalpha
After consistently disappointing shareholders since going public in early 2014, the shares of Sorrento Therapeutics have staged a huge rally recently. (85-4)

NantKwest, NantCell, And Dr. Soon-Shiong's 2020 Cancer Vision

2017-10-11 seekingalpha
Controversial cancer figure Dr. Patrick Soon-Shiong is rapidly gathering a hotbed of some of the very best and lesser known anti-cancer agent candidates engaged in and/or completing clinical trials. (329-24)

BRIEF-Sorrento Therapeutics files for resale by selling stockholders of up to 754K shares of common stock - SEC filing‍​

2017-10-05 reuters
* Sorrento Therapeutics Inc - files for resale by selling stockholders of up to 754,930 shares of common stock - SEC filing‍​ Source text: (bit.ly/2xTIxlX) Further company coverage: (16-3)

Fmr LLC Purchases Shares of 108,789 Sorrento Therapeutics, Inc. (NASDAQ:SRNE)

2017-08-10 rinconhillneighbors.org
Fmr LLC purchased a new position in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 108,789 shares of the biopharmaceutical company’s stock, valued at approximately $430,000. Fmr LLC owned approximately 0.25% of Sorrento Therapeutics at the end of the most recent reporting period. (0-1)

CUSIP: 83587F202